Azora Posts $64.6M Q3 Loss on $57.1M Non-Cash Warrant Charge; Going Concern Stands
Summary
Azora's first post-merger quarter shows a $64.6 million net loss that is mostly a $57.1 million non-cash warrant remeasurement, $22.0 million of cash, and a going-concern warning. AT177's IND and Phase 1a are still slated for the first half of 2027.
Key Events · Earnings and Guidance · ADIL
-
Q3 Loss Driven by Non-Cash Warrant Charge
Net loss was $64.6 million, or $4.52 per share, for the three months ended September 30, 2026; it includes a non-cash $57.1 million change in fair value of the milestone warrant rights liability recorded before those rights were reclassified to equity.
-
Cash of $22.0M Against Going-Concern Doubt
Cash and equivalents were $22.0 million at September 30, 2026, down from $28.7 million at June 30, with a $21.1 million stockholders' deficit; management's substantial-doubt language was disclosed in the concurrent 10-Q.
-
Up to $32.4M From Milestone Warrants
September 16 and September 30 amendments removed a provision reducing investors' milestone warrant purchase rights; up to approximately $32.4 million in gross proceeds could be received if investors elect to purchase, and the operating plan assumes none of it.
-
AT177 IND and Phase 1a Targeted for 1H 2027
IND-enabling studies continue with GMP manufacturing initiated; IND submission and a Phase 1a SAD/MAD trial are planned for the first half of 2027, subject to regulatory clearance.
Analysis · ADIL · Life Sciences
The headline loss is mostly accounting: $57.1 million of the $64.6 million quarterly loss is a non-cash remeasurement of the milestone warrant rights liability, recorded before those rights were reclassified to equity — no cash left the company and no new shares were issued for it. What actually matters is the cash: $22.0 million at September 30 against a $21.1 million stockholders' deficit, with management's going-concern doubt already disclosed in the concurrent 10-Q. The company says existing cash funds IND-enabling studies and the Phase 1a trial without assuming any milestone-warrant proceeds, so the up-to-$32.4 million warrant purchase is optional upside rather than a committed funding source. The AT177 IND and Phase 1a remain targeted for the first half of 2027, making that the next hard checkpoint.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADIL was trading at $4.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.